Oksana B. Kovalevskaya

Oksana B. Kovalevskaya

Auto-generated profile, based on publicly available information

Oksana B. Kovalevskaya

Moscow Research Institute of Psychiatry – branch of the Serbsky National Medical Research Center of Psychiatry and Narcology

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2023 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
TLT. A. Lisitsyna
T. A. Lisitsyna
AAA. A. Abramkin
A. A. Abramkin
DVD. Yu. Veltishchev
D. Yu. Veltishchev
OSO. F. Seravina
O. F. Seravina
OKO. B. Kovalevskaya
O. B. Kovalevskaya
ENE. L. Nasonov
E. L. Nasonov
Background. Interleukin (IL) 6 plays an important role in the pathogenesis of comorbid rheumatoid arthritis (RA) depression, and IL-6 inhibitors (i) used to treat RA patients may have an antidepressant effect.Objective – to evaluate the effectiveness of Russian iIL-6 olokizumab (OKZ) in reducing symptoms of depression in patients with moderate/high RA activity.Material and methods. To date, 49 RA patients have been included, of which 43 (87.7%) are women, with an average age of 47.8±12.8 years; with a predominant high activity of RA according to DAS28 (CRP) indices (89.8%), SDAI (79.6%) and CDAI (75.5%) and inefficacy of stable 12-week therapy of сDMARDs. In all patients, a psychiatrist, in accordance with ICD-10, diagnosed depression (chronic or recurrent) of varying severity during a semi-structured interview. At week 0, all patients were randomized by the method of sequential numbers in a ratio of 1:1:1 to one of the 3 study groups: group 1 – cDMARDs+OKZ 64 mg subcutaneously once every 4 weeks (n=18); group 2 – cDMARDs+OKZ 64 mg subcutaneously once every 4 weeks + psychopharmacotherapy (PPT) (n=26); group 3 – cDMARDs+PPT (n=5). The duration of the study is 24 weeks. The dynamics of depression severity was assessed on the PHQ-9, MADRS scales; anxiety – HAM-A; experimental psychological projective techniques were also used.Results. After 12 and 24 weeks of therapy, there was a significant decrease in the severity of depression and anxiety in all groups of patients. However, the difference between the final and initial values of all scales was statistically significantly greater (p<0.05) in the groups of patients receiving PPT: cDMARDs+OKZ+PPT (ΔPHQ-9 24–0 =–6.75±3.91; ΔMADRS 24–0 =–22.5±4.83; ΔHAM-A 24-0 =–14.6±5.37) and cDMARDs+PPT (ΔPHQ-9 24–0 =–15.5±3.53; ΔMADRS 24–0 =–25.0±1.41; ΔHAM-A 24-0 =–18.5±3.53), compared with the cDMARDs+OKZ group (ΔPHQ-9 24–0 =–4.00±3.89; ΔMADRS 24-0 =–5.75±8.29; ΔHAM-A 24–0 =–8.50±8.21). According to a semi-structured interview with a psychiatrist and design experimental psychological techniques, the proportion of patients without depression after 24 weeks of therapy was significantly higher in the groups of patients receiving PPT: 90% in the group of cDMARDs+OKZ+PPT and 100% – cDMARDs+PPT, as opposed to 25% in the group of cDMARDs+OKZ. OKZ therapy contributed to the normalization of night sleep but did not lead to a decrease in the frequency and severity of cognitive disorders (CD).Conclusions. OKZ has an antidepressant effect in RA patients, leads to a decrease in the frequency of sleep disorders, but a com[1]plete regression of depression symptoms is possible because of the appointment of OKZ without PPT only in 25% of RA patients, mainly in patients with mild depression. Optimal for the complete regression of depression, anxiety and a decrease in the frequency and severity of CD is a combination of OKZ and PPT.

17 June 2022 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
AAAnton A. Abramkin
Anton A. Abramkin
TLTatiana A. Lisitsyna
Tatiana A. Lisitsyna
DVDmitry Yu. Veltishchev
Dmitry Yu. Veltishchev
OSOlga F. Seravina
Olga F. Seravina
OKOksana B. Kovalevskaya
Oksana B. Kovalevskaya
ВЮВельтищев Дмитрий Юрьевич
Вельтищев Дмитрий Юрьевич
Aim. To compare changes in functional limitations in patients with rheumatoid arthritis (RA) and comorbid anxiety and depressive disorders (ADD) treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) alone or in combination with biologic DMARDs (bDMARDs) and/or psychopharmacotherapy (PPT), and to determine predictors of HAQ treatment response. Materials and methods. 128 RA-patients were enrolled, 86% were women with a mean age of 47.411.3 (MSD) years and a median of RA duration 96 [48; 228] months. Disease activity was assessed using DAS28, functional limitations using Health Assessment Questionnaire (HAQ). The Minimal Clinical Important Difference in HAQ was considered to be 0.22. ADD were diagnosed by a licensed psychiatrist in 123 (96.1%) of RA-pts in accordance with ICD-10 in semi-structured interview. Severity of depression and anxiety was evaluated with MontgomeryAsberg Depression Rating Scale and Hamilton Anxiety Rating Scale. RA-pts with ADD were divided into the following treatment groups: 1 сsDMARDs (n=39), 2 сsDMARDs + PPT (sertraline or mianserine; n=43), 3 сsDMARDs + bDMARDs (n=32), 4 сsDMARDs + bDMARDs + PPT (sertraline or mianserine; n=9); 83 (67.5%) patients were assessed at 5-years follow-up. Multivariable logistic regression was performed to determine predictors of HAQ treatment response. Results. Only remission of anxiety and depressive symptoms at 5-yrs endpoint (OR 6.6, 95% CI 1.7824.43, p=0.005), higher baseline HAQ (OR 2.61, 95% CI 1.126.11, p=0.027) and lower baseline BMI (OR 0.9, 95% CI 0.850.96, p=0.001) were independently associated with HAQ treatment response at 5-years follow-up. Conclusion. While ADD do affect functional limitations in patients with RA, PPT tends to attenuate the negative impact of ADD on RA outcomes, and RA patients with functional limitations should therefore be screened for depression and long-term PPT should be recommended.

28 April 2024 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
АBА. В. Borisova
А. В. Borisova
ТLТ. А. Lisitsyna
Т. А. Lisitsyna
DVD. Yu. Veltishchev
D. Yu. Veltishchev
Tatiana Magomedalievna ReshetnyakTatiana Magomedalievna Reshetnyak
Tatiana Magomedalievna Reshetnyak
ОSО. F. Seravina
О. F. Seravina
ОКО. Б. Ковалевская
О. Б. Ковалевская
The aim of this work is to clarify the association between the clinical and psychopathological features of mental disorders (MD) and the clinical and immunological features of antiphospholipid syndrome (APS).Material and methods. The study included 107 patients (34 (31.8%) men and 73 (68.2%) women) aged 18 to 69 years (40.6±10.4 years (M±SD)), 54 (50.5%) – with primary APS (PAPS), established according to the international criteria of 2006 and 53 (49.5%) patients – with reliable diagnosis of systemic lupus erythematosus (SLE), according to the European Alliance of Associations for Rheumatology/American College of Rheumatology (EULAR/ ACR) 2019 criteria, with a secondary APS. Risk of thrombosis in APS was assessed by the GAPSS (Global Anti-Phospholipid Syndrome Score). MD were diagnosed by a psychiatrist in accordance with 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) and Diagnostic and Statistical Manual of mental disorders, 5th edition (DSM-5).Results. Mental disorders are detected in the vast majority of patients with APS (98 (91.6%)), predominantly in anxiety-depressive spectrum disorders (ADSD; 90 (84.1%)). Depressive disorders are not associated with a high risk of thrombosis according to the GAPSS, but more severe variants of depression are more common in patients with high anti-β2 -glycoprotein I (anti-β2 GP1) and low/moderate anti cardiolipin (aCL) antibodies. Anxiety disorders were diagnosed only in patients with a high risk of thrombosis according to GAPSS, high aCL and IgG anti-β2 GP1. Schizotypal disorder was identified only in patients with a high risk of thrombosis and positive anti-phosphatidylserine/prothrombin complex antibodies (aPS/PT) regardless of class, and also more often in patients with high IgG anti-β2 GP1. Epilepsy was observed only in patients with positive aPS/PT, regardless of class. Cognitive impairment (CI), mostly mild and moderate, was found in the vast majority of patients with APS (102 (95.3%)). Dementia was detected in 7 (6.5%) patients, and only in those who had acute or transient cerebrovascular accident. When compared with the general population, dementia developed at an earlier age (up to 65 years). For patients with a high risk of thrombosis, moderate CI is more typical. CI and their severity are not associated with the duration of APS, but are associated with positivity for IgG aPS/PT, acute or transient cerebrovascular accident and the duration of comorbid ADSD.Conclusion. A high frequency of MD in patients with APS revealed. Associations of MD with clinical and immunological manifestations of APS were determined. CI in patients with APS is heterogeneous and are associated with both clinical and immunological manifestations of APS and MD. Identification of CI and determination of their characteristics should be confirmed by clinical, psychopathological and pathopsychological methods in order to personalize their correction within the partnership model of care.

1 January 2022 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
ABA.B. Borisova
A.B. Borisova
DVD.Yu. Veltishchev
D.Yu. Veltishchev
TLT.A. Lisitsyna
T.A. Lisitsyna
Tatiana Magomedalievna ReshetnyakTatiana Magomedalievna Reshetnyak
Tatiana Magomedalievna Reshetnyak
OSO.F. Seravina
O.F. Seravina
AAA.A. Abramkin
A.A. Abramkin
ЦЕЛЬ ИССЛЕДОВАНИЯ Анализ спектра психических расстройств (ПР) и стрессовых факторов, а также особенностей расстройств тревожно-депрессивного спектра (РТДС) у больных системной красной волчанкой (СКВ) и антифосфолипидным синдромом (АФС). МАТЕРИАЛ И МЕТОДЫ В исследование включены 155 пациентов (37 (23,9%) мужчин и 118 (76,1%) женщин) в возрасте от 18 до 69 лет ((M±SD) 37,7±12,3 года). Шестьдесят один (39,3%) больной был с достоверным, согласно критериям EULAR/ACR 2019 г., диагнозом СКВ, 48 (30,9%) — СКВ с вторичным АФС и 46 (29,7%) — с первичным АФС (ПАФС), установленным по международным критериям 2006 г. РЕЗУЛЬТАТЫ У большинства обследованных выявлены ПР (текущее ПР у 145 (93,5%)). Преобладали РТДС: у 58 (95,1%) пациентов с СКВ, у 42 (87,5%) — СКВ с АФС, у 39 (84,8%) — с ПАФС. Больные СКВ чаще, чем больные СКВ с АФС и ПАФС, подвергались стрессовым событиям в детстве (93,4% против 81,2% и 69,6% соответственно; преимущественно родительской депривации), РТДС у этих пациентов развивались в основном в доподростковом возрасте, с тенденцией к хроническим вариантам без ремиссий, что обусловливает большую уязвимость пациентов этой группы к стрессовым событиям по сравнению с больными АФС (p=0,05). ЗАКЛЮЧЕНИЕ Проведенное исследование выявило высокую частоту РТДС и стрессовых факторов у больных СКВ и АФС, связь стрессовых факторов, особенно пережитых в детстве, с провокацией дебюта как РТДС, так и ревматических заболеваний (РЗ), а также негативное влияние РТДС на активность и течение РЗ. Особенностью РТДС у пациентов с СКВ по сравнению с АФС является их возникновение преимущественно в доподростковом возрасте, умеренная выраженность, хроническое течение без ремиссий, обусловливающие большую уязвимость пациентов этой группы к стрессовым событиям в течение жизни. При диагностике и терапии ПР у больных СКВ и АФС особого внимания заслуживает анализ стрессовых ситуаций пациентов, влияющей на формирование общих предрасполагающих и провоцирующих факторов как ПР, так и РЗ, усугубляющей их течение и прогноз.

31 October 2024 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
AAA. A. Abramkin
A. A. Abramkin
TLT. A. Lisitsyna
T. A. Lisitsyna
DVD. Yu. Veltishchev
D. Yu. Veltishchev
OSO. F. Seravina
O. F. Seravina
OKO. B. Kovalevskaya
O. B. Kovalevskaya
ENE. L. Nasonov
E. L. Nasonov
Aim – to assess baseline rates and five-years outcomes of mild cognitive impairments (MCI) in patients with rheumatoid arthritis (RA) and comorbid anxiety and depressive disorders (ADD) receiving conventional synthetic diseasemodifying antirheumatic drugs (csDMARDs) alone or in combination with biologic DMARDs (bDMARDs) and/or adequate psychopharmacotherapy (PPT). To assess factors associated with MCI after five years.Materials and methods. 128 RA patients were enrolled, ADD were diagnosed in 123 (96.1%) by a licensed psychiatrist. Severity of depression and anxiety was evaluated with Montgomery – Asberg and Hamilton Anxiety scales. CI were diagnosed during clinical and psychological examination using the battery of pathopsychological and projective techniques. CI outcomes were considered favourable in cases with no CI diagnosed throughout the study and in cases of CI reversal. PPT was offered, 52 (42.3%) agreed. Patients were divided into the following treatment groups: сsDMARDs (n=39), сsDMARDs + PPT (n=43), сsDMARDs + bDMARDs (n=32), сsDMARDs + bDMARDs + PPT (n=9). Multivariable logistic regression was performed to determine factors associated with CI after five years.Results. MCI were diagnosed in a majority of RA patients (73.2%) including logical thinking impairments (51.2%) and memory deficit (67.5%). At 5-years endpoint 74 patients were included. Total CI rates in no-PPT groups increased from 69 to 85.7% (p=0.037) and were higher compared to PPT groups (85.7% vs 62.5%; р=0.021; RR=1.37). Patients with favourable CI outcomes had lower major depression prevalence and baseline Montgomery – Asberg scores, major improvement in depression symptoms and higher rates of ADD remission after five years. Baseline DAS28 (OR=1.29; р<0.001) was positively associated and remission of ADD negatively associated with MCI after five years (OR=0.25; р=0.03), R2=0.48; p<0.001.Conclusion. ADD and MCI are highly prevalent in RA patients. While CI tend to persist and worsen over time, PPT is associated with reduced risk of CI in long-term perspective. Personalized PPT with antidepressants and neuroleptics may show potential to lessen the rates of MCI in RA patients with ADD.

15 May 2021 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
AAAnton A. Abramkin
Anton A. Abramkin
TLTatiana A. Lisitsyna
Tatiana A. Lisitsyna
DVDmitrii Y. Veltishchev
Dmitrii Y. Veltishchev
OSOlga F. Seravina
Olga F. Seravina
OKOksana B. Kovalevskaya
Oksana B. Kovalevskaya
ВЮВельтищев Дмитрий Юрьевич
Вельтищев Дмитрий Юрьевич
Aim. To assess the influence of psychopharmacotherapy (PPT) of anxiety and depressive disorders on fatigue severity in patients with rheumatoid arthritis (RA). Materials and methods. 128 RA-patients were included. Severity of fatigue was measured with fatigue severity scale (FSS), clinically important fatigue was diagnosed in patients with FSS4. Anxiety and depressive disorders (ADD) were diagnosed by a licensed psychiatrist in 123 (96.1%) of RA-patients in accordance with ICD-10 in semi-structured interview. Severity of depression and anxiety was evaluated with MontgomeryAsberg Depression Rating Scale (MADRS) and Hamilton Anxiety Rating Scale (HAM-A). RA-patients with ADD were divided into the following treatment groups: 1 сDMARDs (n=39), 2 сDMARDs+PPT (sertraline or mianserine), n=43, 3 сDMARDs+bDMARDs (n=32), 4 сDMARDs+bDMARDs+PPT (sertraline or mianserine), n=9. Biologics treatment duration varied from 1 to 5 years, antidepressants from 6 to 96 weeks. 83 (67.5%) RA patients were assessed at five-years follow-up. Multinominal logistic regression analysis was conducted to determine factors associated with clinically important fatigue. Results. Multinominal logistic regression analysis showed clinically important fatigue at baseline to be positively associated (OR 13.57; 95% CI 3.04460.486; p=0.01) and remission of ADD negatively associated (OR 0.162; 95% CI 0.0320.809; p=0.027), with clinically important fatigue at 5 years follow-up (R2=0.385, p0.0001). Conclusion. Due to significant relationship between mental health status, antidepressants treatment and clinically important fatigue in RA-patients, all patients reporting clinically important fatigue should be recommended mental health counselling by a licensed psychiatrist.